药物代谢和药物相互作用体外研究试剂
|
Product Summary
|
|
|
1) CYPxxxR Bactosomes (human) 人细胞色素cytochrome P450 (CYP)
|
|
|
Human CYP co-expressed with human NADPH-CYP reductase in E. coli
|
|
|
Enzyme
|
Product Description
|
|
CYP1A1
|
CYP1A1R Bactosomes
|
|
CYP1A1LR Bactosomes
|
|
|
CYP1A2
|
CYP1A2R Bactosomes
|
|
CYP1A2LR Bactosomes
|
|
|
CYP1B1.1
|
CYP1B1LR Bactosomes
|
|
CYP1B1.3
|
CYP1B1*3LR Bactosomes
|
|
CYP1B1.4
|
CYP1B1*4LR Bactosomes
|
|
CYP2A6
|
CYP2A6R Bactosomes
|
|
CYP2A13
|
CYP2A13LR Bactosomes
|
|
CYP2A13R Bactosomes
|
|
|
CYP2B6
|
CYP2B6BR Bactosomes
|
|
CYP2B6R Bactosomes
|
|
|
CYP2B6LR Bactosomes
|
|
|
CYP2C8
|
CYP2C8BR Bactosomes
|
|
CYP2C8BLR Bactosomes
|
|
|
CYP2C8R Bactosomes
|
|
|
CYP2C8LR Bactosomes
|
|
|
CYP2C9.1
|
CYP2C9BHR Bactosomes
|
|
CYP2C9BR Bactosomes
|
|
|
CYP2C9HR Bactosomes
|
|
|
CYP2C9R Bactosomes
|
|
|
CYP2C9.2
|
CYP2C9*2BR Bactosomes
|
|
CYP2C9*2R Bactosomes
|
|
|
CYP2C9.3
|
CYP2C9*3BR Bactosomes
|
|
CYP2C9*3R Bactosomes
|
|
|
CYP2C18
|
CYP2C18LR Bactosomes
|
|
CYP2C19
|
CYP2C19R Bactosomes
|
|
CYP2C19LR Bactosomes
|
|
|
CYP2D6.1
|
CYP2D6R Bactosomes
|
|
CYP2D6LR Bactosomes
|
|
|
CYP2D6.2
|
CYP2D6*2R Bactosomes
|
|
CYP2D6.10
|
CYP2D6*10R Bactosomes
|
|
CYP2D6.39
|
CYP2D6*39R Bactosomes
|
|
CYP2E1
|
CYP2E1BR Bactosomes
|
|
CYP2E1R Bactosomes
|
|
|
CYP2J2
|
CYP2J2LR Bactosomes
|
|
CYP3A4
|
CYP3A4BR Bactosomes
|
|
CYP3A4BLR Bactosomes
|
|
|
CYP3A4R Bactosomes
|
|
|
CYP3A4LR Bactosomes
|
|
|
CYP3A5
|
CYP3A5BR Bactosomes
|
|
CYP3A5BLR Bactosomes
|
|
|
CYP3A5R Bactosomes
|
|
|
CYP3A5LR Bactosomes
|
|
|
CYP4A11
|
CYP4A11BR Bactosomes
|
|
CYP4A11R Bactosomes
|
|
|
CYP4A11LR Bactosomes
|
|
|
CYP4F2
|
CYP4F2BLR Bactosomes
|
|
All the above products are supplied at 1 nmol CYP per vial.
|
|
|
2) CYPxxxR Easy CYP Bactosomes (human) 人细胞色素 |
|
|
Human CYP co-expressed with human NADPH-CYP reductase in E. coli
|
|
|
Enzyme
|
Product Description
|
|
CYP1A1
|
CYP1A1R EasyCYP Bactosomes
|
|
CYP1A1LR EasyCYP Bactosomes
|
|
|
CYP1A2
|
CYP1A2R EasyCYP Bactosomes
|
|
CYP1A2LR EasyCYP Bactosomes
|
|
|
CYP1B1.1
|
CYP1B1LR EasyCYP Bactosomes
|
|
CYP1B1.3
|
CYP1B1*3LR EasyCYP Bactosomes
|
|
CYP2A6
|
CYP2A6R EasyCYP Bactosomes
|
|
CYP2A13
|
CYP2A13R EasyCYP Bactosomes
|
|
CYP2A13LR EasyCYP Bactosomes
|
|
|
CYP2B6
|
CYP2B6BR EasyCYP Bactosomes
|
|
CYP2B6R EasyCYP Bactosomes
|
|
|
CYP2B6LR EasyCYP Bactosomes
|
|
|
CYP2C8
|
CYP2C8BR EasyCYP Bactosomes
|
|
CYP2C8BLR EasyCYP Bactosomes
|
|
|
CYP2C8R EasyCYP Bactosomes
|
|
|
CYP2C8LR EasyCYP Bactosomes
|
|
|
CYP2C9.1
|
CYP2C9BHR EasyCYP Bactosomes
|
|
CYP2C9BR EasyCYP Bactosomes
|
|
|
CYP2C9HR EasyCYP Bactosomes
|
|
|
CYP2C9R EasyCYP Bactosomes
|
|
|
CYP2C9.2
|
CYP2C9*2BR EasyCYP Bactosomes
|
|
CYP2C9*2R EasyCYP Bactosomes
|
|
|
CYP2C9.3
|
CYP2C9*3BR EasyCYP Bactosomes
|
|
CYP2C9*3R EasyCYP Bactosomes
|
|
|
CYP2C18
|
CYP2C18LR EasyCYP Bactosomes
|
|
CYP2C19
|
CYP2C19R EasyCYP Bactosomes
|
|
CYP2C19LR EasyCYP Bactosomes
|
|
|
CYP2D6.1
|
CYP2D6R EasyCYP Bactosomes
|
|
CYP2D6LR EasyCYP Bactosomes
|
|
|
CYP2D6.2
|
CYP2D6*2R EasyCYP Bactosomes
|
|
CYP2D6.10
|
CYP2D6*10R EasyCYP Bactosomes
|
|
CYP2D6.39
|
CYP2D6*39R EasyCYP Bactosomes
|
|
CYP2E1
|
CYP2E1BR EasyCYP Bactosomes
|
|
CYP2E1R EasyCYP Bactosomes
|
|
|
CYP2J2
|
CYP2J2LR EasyCYP Bactosomes
|
|
CYP3A4
|
CYP3A4BR EasyCYP Bactosomes
|
|
CYP3A4BLR EasyCYP Bactosomes
|
|
|
CYP3A4R EasyCYP Bactosomes
|
|
|
CYP3A4LR EasyCYP Bactosomes
|
|
|
CYP3A5
|
CYP3A5BR EasyCYP Bactosomes
|
|
CYP3A5BLR EasyCYP Bactosomes
|
|
|
CYP3A5R EasyCYP Bactosomes
|
|
|
CYP3A5LR EasyCYP Bactosomes
|
|
|
CYP4A11
|
CYP4A11BR EasyCYP Bactosomes
|
|
CYP4A11R EasyCYP Bactosomes
|
|
|
CYP4A11LR EasyCYP Bactosomes
|
|
|
CYP4F2
|
CYP4F2BLR EasyCYP Bactosomes
|
|
EasyCYP Bactosomes are prepared to a standard specification:
|
|
|
1 nmol CYP per ml; 10 mg total protein per ml; 0.5 nmol CYP per vial
|
|
|
3) Bactosome kits |
|
|
Product Description
|
Contents
|
|
Low Reductase Bactosome Kit
|
1 vial of each of the following Bactosomes:
CYP1A2LR (CYP012); CYP2C9R (CYP006); CYP2C19LR (CYP028); CYP2D6LR (CYP013); CYP3A4LR (CYP010); Control (CYP003) |
|
High Reductase Bactosome Kit
|
1 vial of each of the following Bactosomes:
CYP1A2R (CYP001); CYP2C9HR (CYP019) CYP2C19R (CYP008); CYP2D6R (CYP007) CYP3A4R (CYP002); Control (CYP003) |
|
4) CYPxxxR Bactosomes (dog) |
|
|
Dog CYP co-expressed with dog NADPH-CYP reductase in E. coli
|
|
|
Enzyme
|
Product Description
|
|
CYP1A1
|
Dog CYP1A1LR Bactosomes
|
|
CYP1A2
|
Dog CYP1A2LR Bactosomes
|
|
CYP2B11
|
Dog CYP2B11LR Bactosomes
|
|
CYP2C21
|
Dog CYP2C21LR Bactosomes
|
|
CYP2C41
|
Dog CYP2C41LR Bactosomes
|
|
CYP2D15
|
Dog CYP2D15LR Bactosomes
|
|
CYP3A12
|
Dog CYP3A12LR Bactosomes
|
|
CYP3A26
|
Dog CYP3A26LR Bactosomes
|
|
All the above products are supplied at 1 nmol CYP per vial.
|
|
|
5) Control preparations |
|
|
Product Description
|
Size
|
|
Control Bactosomes
|
10 mg protein
|
|
Control EasyCYP Bactosomes
|
5 mg protein
|
|
Reductase Bactosomes
|
4 nmol reductase
|
|
Control cytosol
|
1 mg protein
|
|
Control EasyCYP Bactosomes are supplied at a standard protein concentration of 10 mg per ml.
|
|
|
Control cytosol is supplied at a standard protein concentration of 10 mg per ml.
|
|
|
6) Other enzymes |
|
|
Product Description
|
Size
|
|
Human SULT1A1*1
|
1 mg cytosolic
|
|
Human SULT1A1*2
|
1 mg cytosolic
|
|
Human SULT1A2
|
1 mg cytosolic
|
|
Human SULT1A3
|
1 mg cytosolic
|
|
Human SULT1B1
|
1 mg cytosolic
|
|
Human SULT1C2
|
1 mg cytosolic
|
|
Human SULT1C4
|
1 mg cytosolic
|
|
Human SULT1E1
|
1 mg cytosolic
|
|
Human SULT2A1
|
1 mg cytosolic
|
|
Human GSTA1
|
1 mg cytosolic
|
|
Human GSTM1
|
1 mg cytosolic
|
|
Human aldehydeoxidase
|
250 μl cytosoli
|
|
Human aldehydedehydrogenase 1A1
|
1 mg cytosolic
|
|
Human carboxylesterase 1 (CES1)
|
1 mg membran
|
|
Human carboxylesterase 2 (CES2)
|
1 mg membran
|
|
Human UGT1A6 Bactosomes
|
5 mg membran
|
|
7) Antibodies (other than Nosan antibodies) |
|
|
Product Description
|
Size
|
|
Pre-immune sheep serum
|
50 μl
|
|
Polyclonal sheep anti-rat UGT antiserum
|
50 μl
|
|
Polyclonal sheep anti-human SULT1A3 antiserum
|
50 μl
|
8) Chemicals |
||
| Product Description | Size | |
| 4’-hydroxydiclofenac, > 98% | 0.1 mg | CYP2C9 metabolite of diclofenac |
| 5 mg | ||
| 6α-hydroxypaclitaxel, > 97% | 0.1 mg | CYP2C8 metabolite of paclitaxel |
| 5 mg | ||
| [1-14C] lauric acid, > 98%, 49.4 mCi/mmol | 1.85 MBq(50 μCi) | Substrate for CYP2E1 and CYP4A11. |
| [1-14C] 11-hydroxylauric acid, > 98%, 51.8 mCi/mmol | 1.85 MBq(50 μCi) | CYP2E1 metabolite of lauric acid (minor metabolite of CYP4A11). |
| [1-14C] 12-hydroxylauric acid, > 98%, 50.8 mCi/mmol | 1.85 MBq | CYP4A11 metabolite of lauric acid. |
| Tolbutamide, > 98% | 100 mg | Substrate for CYP2C. |
| Hydroxytolbutamide, > 98% | 10 mg | CYP2C metabolite of tolbutamide. |
| Carboxytolbutamide, > 98% | 10 mg | Metabolite of tolbutamide. |
| Carboxytolbutamide methyl ester, > 98% | 10 mg | Derivative of carboxytolbutamide, a metabolite of tolbutamide. |
| Tolbutamide kit (containsTolbutamide Hydroxytolbutamide Carboxytolbutamide Carboxytolbutamide methyl ester), > 98% | 100 mg of tolbutamide, 10 mg each of metabolites. | Tolbutamide Hydroxytolbutamide Carboxytolbutamide >Carboxytolbutamide methyl ester |
| 7-ethoxyresorufin, > 98% | 10 mg | Substrate for CYP1A1, CYP1A2 and CYP1B1. |
| Resorufin, > 98% | 100 mg | CYP1A1, CYP1A2 and CYP1B1 metabolite of 7-ethoxyresorufin. |
| 7-benzyloxyquinoline (7BQ), > 98% | 10 mg | Substrate for CYP3A4. |
| 7-hydroxyquinoline (7HQ), > 98% | 10 mg | Metabolite of 7-BQ. |
| [3-14C] 7-ethoxycoumarin, 46.0 mCi/mmol, > 99% | 1.85 MBq (50 μCi) | CYP substrate |
| MAMC, > 98% | 10 mg | Substrate for CYP2D6. |
| 25 mg | ||
| HAMC, > 98% | 10 mg | CYP2D6 metabolite of MAMC. |
| 7-methoxy-4-(trifluoromethyl)-coumarin (MFC), > 98% | 10 mg | Substrate for CYP2C9. |
| 25 mg | ||
| 7-benzyloxy-4-(trifluoromethyl)-coumarin (BFC), > 98% | 10 mg | Substrate for CYP3A4. |
| 25 mg | ||
| 7-hydroxy-4-(trifluoromethyl)-coumarin (HFC), > 98% | 10 mg | Metabolite of MFC and BFC. |
| Omeprazole, > 98% | 1 g | Substrate of CYP2C19. |
| 3-O-methylfluorescein, > 98% | 10 mg | Substrate of CYP1A1 and CYP2C19. |
| 25 mg | ||
| Tienilic acid, > 98% | 10 mg | Mechanism-based inhibitor of CYP2C9. |
| 25 mg | ||
| Paclitaxel, > 98% | 25 mg | Substrate of CYP2C8. |
| 100 mg | ||
| Ketoconazole, > 98% | 100 mg | CYP3A4 inhibitor. |
| 1 g | ||
| Diclofenac, > 98% | 10 g | Substrate of CYP2C9 and CYP2C18. |
| Amodiaquine dihydrochloride dihydrate, > 98% | 5 g | Substrate of CYP2C8. |
| Desethylamodiaquine, > 98% | 10 mg | CYP2C8 metabolite of amodiaquine. |
| 25 mg | ||
| Terfenadine, > 98% | 5 g | Substrate of CYP3A4 and CYP2J2 |
| (-)-N-3-benzylphenobarbital, > 98% | 10 mg | Specific inhibitor of CYP2C19. |
| 25 mg | ||
| Montelukast sodium | 10 mg | Inhibitor of CYP2C8. |
| 25 mg | ||
 |
 |
 |
| 官网：www.cxbio.com | 微信服务号：iseebio | 微博：seebiobiotech |
 |
 |
 |
| 商城：mall.seebio.cn | 微信订阅号：seebiotech | 泉养堂：www.canmedo.com |
相关资讯
- Fertil Steril：COVID-19可以通过生殖系统传播吗？
- 重组胰蛋白酶检测试剂盒
- 全球首例！脑电刺激成功拯救重度抑郁症患者，治愈抑郁症时代离我们不远了？
- 多运动就一定好吗？Cell子刊：过度运动会导致健康人的线粒体功能受损并降低葡萄糖耐量
- 钙依赖性重组蛋白
- iMatrix-221
- 利用CRISPR/Cas9有望让猪成为病人的器官供者
- Sci Transl Med：新突破！科学家揭秘microRNA分子保护机体血管完整性的分子机制！
- 高存活率细胞冻存液 CryoScarless(R)DMSO-Free
- 富含橄榄油的地中海饮食或有助于降低乳腺癌风险
新进产品
同类文章排行
- 生物钟蛋白相关抗体
- GlyScope Series 标签试剂盒
- 神经节苷脂
- 凝集素
- 抗聚糖抗体
- WESTERNVIEW(TM) Detection Kits
- 抗Siaα2-3，单克隆抗体（HYB4） Anti Siaα2-3, Monoclonal Antibody (HYB4)
- 蛋白质快速测定试剂盒Wako II（Protein Assay Rapid Kit Wako II）
- 免疫印迹用化学发光试剂 ImmunoStar(R) 系列
- PA tag相关产品 标记抗PA tag抗体
资讯文章
您的浏览历史
